Cellectar Biosciences Inc. (CLRB)
CLRB trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | CLRB on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001279704 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These uncertainties raise substantial doubt about the Company's ability to continue as a going concern." | 10-Q 2026-11-10 |
| Cash and burn | $24.6M cash; operating cash flow -$6.2M a quarter. | Report 2026-09-30 |
| Shares outstanding | 10,039,183 (2026-11-06); 4,240,134 a year earlier; 12,288,325 three years earlier. 3y figure adjusted for splits (1-for-30 overall). | Cover page 2026-11-06 |
| Reverse splits, 3 years | 1; latest 1-for-30 on 2025-06-24 | Source 2025-06-24 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-05-06 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, Morristown, New Jersey, United States | PCAOB Form AP 2026-03-17 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $25K, sold $733 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$8.0M | -$9.4M | $24.6M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q2 2026 2026-06-30 | Not filed | -$6.9M | -$6.0M | $34.0M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q1 2026 2026-03-31 | Not filed | -$5.7M | -$4.8M | $8.3M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q4 2025 2025-12-31 | Not filed | -$5.3M | -$4.3M | $13.2M | No debt tags | Needs four quarters | 10-K 2026-03-04 |
| Q3 2025 2025-09-30 | Not filed | -$4.4M | -$4.3M | $12.6M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q2 2025 2025-06-30 | Not filed | -$5.4M | -$5.1M | $11.0M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q1 2025 2025-03-31 | Not filed | -$6.6M | -$9.4M | $13.9M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q4 2024 2024-12-31 | Not filed | -$2.4M | -$10.9M | $23.3M | No debt tags | Needs four quarters | 10-K 2026-03-04 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-06-02 |
| Latest annual report | 10-K/A | 2026-04-30 |
| Latest quarterly / interim | 10-Q | 2026-11-10 |
| Latest current report FORM 8-K | 8-K | 2026-11-10 |
| Latest proxy | DEFA14A | 2026-05-28 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -8.8% |
| 1 month | -18.0% |
| 3 months | -54.0% |
| Year to date | -61.4% |
| 1 year | -60.3% |
| From 52-week high | -71.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| AEON | AEON Biopharma Inc. | $0.1407 | -8.04% | $10.1M |
| BFRI | Biofrontera Inc. | $0.5700 | -18.58% | $10.2M |
| HIND | Vyome Holdings Inc. | $1.53 | -3.16% | $10.7M |
| PTN | Palatin Technologies Inc. | $6.13 | -1.69% | $10.9M |
| LEXX | Lexaria Bioscience Corp. | $4.41 | -0.68% | $9.3M |
| RADX | Radiopharm Theranostics Limited | $0.7676 | +1.00% | $11.1M |
| GDTC | CytoMed Therapeutics Limited | $0.7739 | -6.68% | $9.2M |
| ASBP | Aspire-Lakewood Holdings Inc. | $8.06 | -5.29% | $11.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier